Text Size

DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation

This study has been completed.
Sponsor:
Information provided by:
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00083915
First received: June 3, 2004
Last updated: July 7, 2011
Last verified: July 2011
History of Changes
Results First Received: July 7, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Interventions: Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Adriamycin
Drug: Etoposide
Drug: Melphalan
Drug: Thalidomide
Drug: Dexamethasone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
High Dose Melphalan No text entered.
Mel-DT PACE No text entered.

Participant Flow:   Overall Study
    High Dose Melphalan     Mel-DT PACE  
STARTED     52     45  
COMPLETED     2     8  
NOT COMPLETED     50     37  
Death                 6                 3  
Physician Decision                 11                 6  
Withdrawal by Subject                 8                 3  
disease progression                 18                 23  
Failure to collect                 3                 0  
No response                 3                 1  
Insurance issues                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
High Dose Melphalan No text entered.
Mel-DT PACE No text entered.
Total Total of all reporting groups

Baseline Measures
    High Dose Melphalan     Mel-DT PACE     Total  
Number of Participants  
[units: participants]
 		  52     45     97  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     27     24     51  
>=65 years     25     21     46  
Age  
[units: years]
Mean ± Standard Deviation 		  64.83  ± 8.77     65.5  ± 8.36     65.14  ± 8.55  
Gender  
[units: participants]
 		     
Female     22     19     41  
Male     30     26     56  



  Outcome Measures

1.  Primary:   Transplant With DT PACE-Melphalan Regimen of Chemotherapy vs. Transplant With Melphalan Alone.   [ Time Frame: 3 years depending on start date ]
  Show Outcome Measure 1

2.  Secondary:   Side Effects With DT PACE-Melphalan vs Side Effects With Melphalan Alone   [ Time Frame: 3 years depending on start date ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Nathan M. Petty
Organization: University of Arkansas for Medical Sciences, Myeloma Institute
phone: 501-526-6990 ext 2461
e-mail: pettynathanm@uams.edu


No publications provided


Responsible Party: Nathan Petty, MS, University_Of_Arkansas
ClinicalTrials.gov Identifier: NCT00083915     History of Changes
Other Study ID Numbers: UARK 2001-12
Study First Received: June 3, 2004
Results First Received: July 7, 2011
Last Updated: July 7, 2011
Health Authority: United States: Food and Drug Administration